Mediwound Ltd. (MDWD) — SEC Filings
Mediwound Ltd. (MDWD) — 35 SEC filings. Latest: 6-K (Apr 2, 2026). Includes 25 6-K, 5 SC 13G/A, 2 20-F.
View Mediwound Ltd. on SEC EDGAR
Overview
Mediwound Ltd. (MDWD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 6-K filed on Apr 2, 2026: MediWound Ltd. filed a 6-K report on April 2, 2026, detailing its status as a foreign issuer. The filing includes standard report documents and exhibits, with its principal business address located at 42 Hayarkon Street, Yavne, Israel.
Sentiment Summary
Across 35 filings, the sentiment breakdown is: 3 bullish, 32 neutral. The dominant filing sentiment for Mediwound Ltd. is neutral.
Filing Type Overview
Mediwound Ltd. (MDWD) has filed 25 6-K, 2 20-F, 5 SC 13G/A, 1 SC 13G, 1 SC 13D/A, 1 SC 13D with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (35)
Risk Profile
Risk Assessment: Of MDWD's 27 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Key Executives
- Nachum (Homi) Shamir
- Ofer Gonen
- Chief Medical Officer
- Gili Harir
- Sharon Malka
- Len Blavatnik
- Kristin Hedlund
Top Tags
sec-filing (6) · financial-results (5) · foreign-private-issuer (5) · shareholder-meeting (4) · regulatory-filing (3) · 6-K (3) · corporate-update (3) · capital-raise (3) · corporate-governance (3) · filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Ordinary Shares Offered | 1,734,105 | Number of shares sold in the offering on September 29, 2025. |
| Registered Direct Offering | $30.0M | Funds raised by MediWound Ltd. |
| Shares Purchased | 11,200 | Total ordinary shares bought by executives. |
| Average Price | $17 | Average price per share paid by executives. |
| Total Value | $190,400 | Calculated total value of shares purchased (11,200 shares * $17/share). |
| Interest Rate on Deposits | 5.45%-6.39% | Annual interest for restricted bank deposits in 2024. |
| Finished Goods Write-down | $216 | Amount written down for finished goods as of December 31, 2024. |
| One-time Expenses | $309 | Expenses incurred in 2022 related to management changes. |
| Commission File Number | 001-36349 | Identifies the specific SEC filing for MediWound Ltd. |
| Financial Period | Q2 2024 | Results for the second quarter of 2024 are detailed. |
| Year of Board Changes | 2023 | Three members left, one joined. |
| Total Board Members (End of 2023) | 5 | After changes in 2023. |
| Year of Key Officer Replacements | 2023 | Two key officers were replaced. |
| Total Key Officers (End of 2023) | 6 | After replacements. |
| CMO Bonus Payment | $120 | Recorded in December 2022. |
Forward-Looking Statements
- {"claim":"MediWound's stock price will see an increase due to these positive clinical trial results.","entity":"MediWound Ltd.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"EscharEx® will gain increased market share in the wound care segment.","entity":"EscharEx®","targetDate":"Q4 2024","confidence":"medium"}
Frequently Asked Questions
What are the latest SEC filings for Mediwound Ltd. (MDWD)?
Mediwound Ltd. has 35 recent SEC filings from Jan 2024 to Apr 2026, including 25 6-K, 5 SC 13G/A, 2 20-F. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of MDWD filings?
Across 35 filings, the sentiment breakdown is: 3 bullish, 32 neutral. The dominant sentiment is neutral.
Where can I find Mediwound Ltd. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Mediwound Ltd. (MDWD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Mediwound Ltd.?
Financial highlights for Mediwound Ltd. are available when 10-K or 10-Q filings are enriched with AI analysis. Check back as new filings are processed.
What is the investment thesis for MDWD?
The investment thesis for MDWD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Mediwound Ltd.?
Key executives identified across Mediwound Ltd.'s filings include Nachum (Homi) Shamir, Ofer Gonen, Chief Medical Officer, Gili Harir, Sharon Malka and 2 others.
What are the main risk factors for Mediwound Ltd. stock?
Of MDWD's 27 assessed filings, 0 were flagged high-risk, 8 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Mediwound Ltd.?
Recent forward-looking statements from Mediwound Ltd. include guidance on {"claim":"MediWound's stock price will see an increase due to these positive clinical trial results.","entity":"MediWoun and 1 other predictions.